Lyell Immunopharma, Inc. (LYEL) — 8-K Filings

8-K Filings (19)

• Lyell Immunopharma Files 8-K for Other Event — Dec 8, 2025 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on December 8, 2025, reporting an "Other Event" that occurred on December 7, 2025. The filing does not provide specific de
• 8-K Filing — Dec 5, 2025
• 8-K Filing — Nov 10, 2025
• Lyell Immunopharma Files 8-K on Executive Changes — Nov 3, 2025 Risk: low
  Lyell Immunopharma, Inc. filed an 8-K on November 3, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of ce
• Lyell Immunopharma Reports Leadership Changes — Sep 16, 2025 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on September 16, 2025, reporting changes in its board of directors and certain officers, as well as updates to compensator
• Lyell Immunopharma Files 8-K on Material Agreement — Jul 25, 2025 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on July 25, 2025, reporting on events that occurred on July 24, 2025. The filing indicates the entry into a material defin
• Lyell Immunopharma Reports Unregistered Equity Sales — Jun 26, 2025 Risk: medium
  On June 20, 2025, Lyell Immunopharma, Inc. filed an 8-K report detailing unregistered sales of equity securities. The filing does not specify the number of shar
• Lyell Immunopharma Files 8-K Report — Jun 17, 2025 Risk: medium
  On June 17, 2025, Lyell Immunopharma, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regar
• Lyell Immunopharma Announces Board and Executive Changes — Jun 9, 2025 Risk: low
  Lyell Immunopharma, Inc. announced on June 9, 2025, changes in its board and executive compensation. The filing details the departure of directors, election of
• Lyell Immunopharma Files 8-K — May 28, 2025 Risk: low
  Lyell Immunopharma, Inc. filed an 8-K on May 28, 2025, reporting a material modification to the rights of security holders and financial statements/exhibits. Th
• Lyell Immunopharma Files 8-K on Shareholder Votes — May 21, 2025 Risk: low
  Lyell Immunopharma, Inc. filed an 8-K on May 21, 2025, reporting on matters submitted to a vote of security holders as of May 15, 2025. The filing details the c
• Lyell Immunopharma Files 8-K on Corporate Changes — Apr 1, 2025 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on March 27, 2025, reporting on cost associated with exit or disposal activities, departure of directors or certain office
• Lyell Immunopharma Fails Nasdaq Listing Standards — Jan 24, 2025 Risk: high
  Lyell Immunopharma, Inc. filed an 8-K on January 23, 2025, to report its failure to meet the continued listing standards of the Nasdaq Stock Market. The company
• Lyell Immunopharma Files 8-K — Dec 10, 2024 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on December 10, 2024, reporting an event that occurred on December 9, 2024. The filing is categorized under 'Other Events'
• Lyell Immunopharma Reports Board and Executive Changes — Nov 26, 2024 Risk: medium
  Lyell Immunopharma, Inc. announced on November 22, 2024, a change in its board of directors and executive compensation arrangements. Specifically, the company r
• Lyell Immunopharma Files 8-K on Agreements and Asset Changes — Oct 31, 2024 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on October 31, 2024, reporting on several key events. These include entering into a material definitive agreement, the com
• Lyell Immunopharma Files 8-K with Key Agreements and Equity Sales — Oct 24, 2024 Risk: medium
  Lyell Immunopharma, Inc. filed an 8-K on October 24, 2024, reporting on several key events. These include entering into a material definitive agreement, unregis
• Lyell Immunopharma Files 8-K with Financials — Jun 26, 2024 Risk: low
  Lyell Immunopharma, Inc. filed an 8-K on June 26, 2024, reporting on various events. The filing includes financial statements and exhibits, and is categorized u
• Lyell Immunopharma Files 8-K on Shareholder Vote Matters — Jun 14, 2024 Risk: low
  Lyell Immunopharma, Inc. filed an 8-K on June 14, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific d

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX